AR089833A1 - Biomarcador predictivo para el tratamiento del cancer con anticuerpos de adcc incrementada - Google Patents

Biomarcador predictivo para el tratamiento del cancer con anticuerpos de adcc incrementada

Info

Publication number
AR089833A1
AR089833A1 ARP130100257A ARP130100257A AR089833A1 AR 089833 A1 AR089833 A1 AR 089833A1 AR P130100257 A ARP130100257 A AR P130100257A AR P130100257 A ARP130100257 A AR P130100257A AR 089833 A1 AR089833 A1 AR 089833A1
Authority
AR
Argentina
Prior art keywords
level
treatment
nkp46
infiltration
cells
Prior art date
Application number
ARP130100257A
Other languages
English (en)
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of AR089833A1 publication Critical patent/AR089833A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente se refiere a métodos para identificar qué pacientes diagnosticados con cáncer se beneficiarán más del tratamiento con una terapia anticáncer que comprende un anticuerpo de ADCC incrementada. Reivindicación 1: Método para predecir la respuesta de un paciente de cáncer al tratamiento con un anticuerpo de ADCC incrementada, que comprende determinar el nivel de infiltración de células NKp46+ en el tumor del paciente previamente al tratamiento y comparar dicho nivel de infiltración de células NKp46+ con un nivel de referencia, en el que un nivel más alto de infiltración de células NKp46+ en comparación con el nivel de referencia es indicativo de que un paciente obtendrá un beneficio clínico del tratamiento. Reivindicación 9: Kit para detectar el nivel de infiltración de células NKp46+ en un tumor, comprendiendo el kit: i) uno o más compuestos para detectar el nivel de infiltración de células NKp46+, y ii) instrucciones para utilizar dicho kit en el método según las reivindicaciones 1 a 8. Reivindicación 11: Anticuerpo de ADCC incrementada para la utilización en el tratamiento del cáncer en un paciente, en el que i) el nivel de infiltración de células NKp46+ en el tumor del paciente se determina previamente al tratamiento, ii) el nivel de infiltración de células NKp46+ se compara con un nivel de referencia, y iii) el anticuerpo de ADCC incrementada se administra en un paciente que presenta un nivel de infiltración de células NKp46+ que es más alto que el nivel de referencia. Reivindicación 19: Método para el tratamiento del cáncer en un paciente, en el que: i) el nivel de infiltración de células NKp46+ en el tumor del paciente se determina previamente al tratamiento, ii) el nivel de infiltración de células NKp46+ se compara con un nivel de referencia, y iii) el anticuerpo de ADCC incrementada se administra en un paciente que presenta un nivel de infiltración de células NKp46+ que es más alto que el nivel de referencia. Reivindicación 20: Composición farmacéutica que comprende un anticuerpo de ADCC incrementada para el tratamiento de un paciente de cáncer que presenta un nivel de infiltración de células NKp46+ en el tumor previamente al tratamiento que se encuentra incrementado respecto a un nivel de referencia.
ARP130100257A 2012-01-31 2013-01-29 Biomarcador predictivo para el tratamiento del cancer con anticuerpos de adcc incrementada AR089833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12153197 2012-01-31

Publications (1)

Publication Number Publication Date
AR089833A1 true AR089833A1 (es) 2014-09-17

Family

ID=47683696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100257A AR089833A1 (es) 2012-01-31 2013-01-29 Biomarcador predictivo para el tratamiento del cancer con anticuerpos de adcc incrementada

Country Status (3)

Country Link
US (1) US20130195854A1 (es)
AR (1) AR089833A1 (es)
WO (1) WO2013113641A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
KR20230154235A (ko) * 2021-03-05 2023-11-07 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 NKp46에 대한 항체 및 이의 적용

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2513797C (en) 2003-01-22 2016-05-03 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
ES2755976T3 (es) 2005-02-07 2020-04-24 Roche Glycart Ag Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas

Also Published As

Publication number Publication date
WO2013113641A1 (en) 2013-08-08
US20130195854A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
Geng et al. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer
JP2014144959A5 (es)
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
RU2015125575A (ru) Композиции и способы для лечения злокачественной опухоли
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2013068373A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
RU2013106938A (ru) Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы
WO2018183817A3 (en) Tumor burden as measured by cell free dna
RU2013106940A (ru) Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака поджелудочной железы
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
WO2017217807A3 (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
BR112018069316A2 (pt) métodos para detectar presença de pelo menos uma espécie de bordetella patogênica e selecionar um paciente que exibe sintomas semelhantes à coqueluche, e, kit para detectar presença de pelo menos uma espécie de bordetella patogênica.
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
BR112015027249A2 (pt) método de diagnóstico de câncer
AR089833A1 (es) Biomarcador predictivo para el tratamiento del cancer con anticuerpos de adcc incrementada

Legal Events

Date Code Title Description
FB Suspension of granting procedure